Leptomeningeal and medullary response to second-line erlotinib in lung adenocarcinoma

J Thorac Oncol. 2008 Jun;3(6):677-9. doi: 10.1097/JTO.0b013e3181757a8b.
No abstract available

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / diagnosis
  • Adenocarcinoma / drug therapy
  • Adenocarcinoma / secondary*
  • Cerebrospinal Fluid / cytology
  • Diagnosis, Differential
  • Dose-Response Relationship, Drug
  • ErbB Receptors / antagonists & inhibitors
  • Erlotinib Hydrochloride
  • Female
  • Follow-Up Studies
  • Humans
  • Lung Neoplasms / diagnostic imaging
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / pathology*
  • Magnetic Resonance Imaging
  • Meningeal Neoplasms / diagnosis
  • Meningeal Neoplasms / drug therapy
  • Meningeal Neoplasms / secondary*
  • Middle Aged
  • Protein Kinase Inhibitors / administration & dosage
  • Protein Kinase Inhibitors / therapeutic use*
  • Quinazolines / administration & dosage
  • Quinazolines / therapeutic use*
  • Tomography, X-Ray Computed

Substances

  • Protein Kinase Inhibitors
  • Quinazolines
  • Erlotinib Hydrochloride
  • ErbB Receptors